Evaluation of Plasma Creatine Phosphokinase (CPK) Level Following a Single Injection of Methotrexate as a Predicator of Treatment Success in Ectopic Pregnancy

Leila Safdarian; M.D., Marzieh Aghahosseini; M.D., Ashraf Alleyassin; M.D, Mina Kohbodi; M.D
Department of Obstetrics & Gynecology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Received February 2013; revised & accepted May 2013

Abstract
Objective: To evaluate the plasma creatine phosphokinase (CPK) level after a single injection of methotrexate (MTX) as a predictor of treatment success in ectopic pregnancy (EP).

Materials and methods: In this prospective study, seventy nine women older than 18 years treated with methotrexate for ectopic pregnancy were evaluated for CPK and β-subunit of human chorionic gonadotropin (βhCG) levels, while they received intramuscular MTX at a dose of 50 mg/m2. The day of injection was considered as day 1 (D1). CPK level on D1 was compared between the group 1 (as treatment success group), treated by a single MTX injection, and the group 2, treated by two or three MTX injections or by surgery.

Results: The success rate of MTX treatment was 58 (73.3%). The mean of CPK was higher in treatment success group (group 1) than failure group (group 2) (71.98 ± 15.711 vs. 64.43 ± 15.898), but the difference was not significant (p=0.06). The mean of βhCG was significantly lower in treatment success group (group 1) than failure group (group 2) (1187.52±631.45 vs. 1663.87±1096.845; p=0.01). Ultrasonographic findings of EP were seen in 63 patients, while the means of βHCG and CPK were higher in these patients than those with normal ultrasonography, but difference was not significant (p=0.37 and p=0.24, respectively).

Conclusion: The sample was not large enough to indicate a significant difference in the CPK level, which can be considered as an indicator for differentiating between the successful and unsuccessful treatment groups. Moreover, the present study did not show any relation between initial β-hCG and CPK serum levels, so our findings indicate that they are not possibly considered as two independent biomarkers in ectopic pregnancy.

Keywords: Methotrexate, CPK, Ectopic Pregnancy, Treatment

Introduction
Ectopic pregnancy (EP) is a life threatening condition with incidence of 2% in the general population (1). It is still the most important cause of first trimester maternal deaths, and is responsible for 73% of early pregnancy mortalities (2). Treatment of ectopic pregnancy (EP) with methotrexate (MTX) is an alternative to surgery (3, 4). Several studies have shown the use of methotrexate (MTX) is safe for treatment of early unruptured EP in properly selected
cases, while the risk of failure is the principal disadvantage, which then requires surgery (4,5). Methotrexate is an antagonist of folic acid that inhibits dihydrofolic acid reductase interfering with DNA synthesis, repair, and cellular replication. Trophoblasts (rapidly proliferating tissues) are very sensitive to these MTX effects (6, 7). After a single dose (50 mg/m2) delivered by intramuscular injection (IM), the success rate of methotrexate treatment ranges from 64% to 94% (3). However, depending on patient selection criteria and different management, success rates may vary (5-8).

The first studies of MTX treatment for EP were conducted by Tanaka et al. (1982)(9) and Ory et al. (1986)(10). Prior studies indicated complete resolution of ectopic pregnancies in 94.2% of patients. Furthermore, they signified a very auspicious fertility rate among patients following this treatment, and indicated that 87.2% of them consequently had intrauterine pregnancies (11, 12).

The most commonly predictors of failure cited in these studies are serum human chorionic gonadotropin (β-hCG) progesterone levels, ectopic mass size, and the presence of ectopic cardiac activity (8, 13-15). Creatine phosphokinase (CPK) is an intracellular enzyme in muscle cells and its level increases in plasma in cases of muscle lysis, hence it is suitable for evaluation of the risk of tubal rupture in EP (16-18). A possible description is the presence of CPK inside trophoblastic cells. The elevated CPK would then be due to the trophoblastic invasion and the trophoblastic volume (16). The lysis of trophoblastic cells causes the plasma CPK level to increase; therefore, probability of a higher success rate for a single MTX dose is also greater (9-11, 16-18).

Improvement of modalities of early diagnosis and treatment can reduce both mortality and morbidity of ectopic pregnancy. In this prospective study, we evaluated the plasma creatine phosphokinase (CPK) level after a single injection of methotrexate as a predictor of treatment success in ectopic pregnancy.

**Materials and methods**

We conducted this prospective study at Obstetrics and Gynecology Clinic of Shariati Hospital, Tehran, Iran, from 2011 to 2012. Seventy nine women older than 18 years treated with MTX for EP were eligible for this study. The study protocol was approved by Committee of Ethics for Research in Obstetrics and Gynecology at Tehran University of Medical Sciences (TUMS). The study procedure was explained for all patients, and informed written consent was given before enrollment.

We enrolled patients referred to the center for pelvic pain and/or vaginal bleeding along with positive pregnancy test (EP suspicious). This diagnosis was confirmed with plasma β-hCG level higher than 2,000 IU/L without any visible intrauterine pregnancy documented by sonography test. In addition, the findings of sonography only revealed an inhomogeneous adnexal mass, an empty gestational sac with a hyperechoic ring.

MTX therapy included the following criteria: absence of embryonic cardiac activity detected by transvaginal ultrasonography, β-hCG concentration <5,000 mIU/mL, ectopic pregnancy <4 cm in size as visualized by transvaginal ultrasonography, and the ability to participate in the follow-up.

Exclusion criteria were as follows: age under 18, severe systemic disease as acquired immune deficiency syndrome (AIDS), hepatitis and contraindications of MTX treatment in EP, like hepatic renal failure; thrombocytopenia; anemia; or any suspicion of tubal rupture (hemodynamic instability, severe pain, or detection of large hemoperitoneum by sonography).

The CPK and β-subunit of hCG (βhCG) level were measured in all included patients, then they received intramuscular MTX at a dose of 50 mg/m2. The day of injection was considered day 1 of the protocol (D1). Patients with suspected tubal rupture during treatment, or who refused second or third MTX injections were planned to undergo surgery. In addition, the need for surgery was determined by the surgeons blinded to the D1 plasma CPK level.

The measurements of βhCG titer were repeated on days 3 and 7 after the injection.

If the levels decreased by more than 15% between days 1 and 4 or between days 4 and 7, the patient were discharged, while the levels were subsequently measured at an ambulatory clinic. However, if βhCG titer decreased by less than 15%, (plateau levels), or rose between days 4 and 7, another MTX injection was offered. As stated earlier, hemodynamic instability, severe pain, and signs of peritoneal irritation were indications for immediate surgical intervention at any stage of the treatment protocol.

CPK levels on D1 were compared between group 1 (as treatment success group), treated by a single MTX injection, and group 2, treated by two or three MTX injections or by surgery.
The receiver operator characteristics curve was analyzed to assess the performance of the CPK level on D1 between groups 1 and 2.

Categorical variables were compared using the $\chi^2$ test, and continuous variables were compared using Student’s t test. Correlation was tested by Spearman’s rho. Differences were considered significant at $p<0.05$.

**Results**

Totally, we evaluated 79 women with mean age of 28.7±3.42 and mean gestational age of 45.6±4.51 (Table 1). The mean of initial $\beta$-hCG was 1314.14±802.943 and the mean of CPK was 69.97±11.993. The success rate of MTX treatment was 58 (73.3%). The correlation between $\beta$-hCG and gestational age ($p=0.035$), and follow up duration and time to negative $\beta$-hCG ($p=0.001$) were significant. The correlation among CPK with gestational age ($p=0.11$), $\beta$-hCG ($p=0.59$) and time to negative $\beta$-hCG ($p=0.12$) were not significant. CPK and $\beta$-hCG revealed no significant correlation with age, gravity, parity, follow up duration, EP history, abortion history and infertility history (Tables 1 & 2). Moreover, the serum level of $\beta$-hCG and CPK did not show significant difference between normal and infertile patients ($P=0.86$ and $P=0.49$ respectively) (Table 2).

The levels of $\beta$-hCG and CPK did not correlate significantly with clinical characteristics; however, the correlation between $\beta$-hCG with spotting was significant ($p=0.021$). Our results confirmed that 63 patients showed ultrasonographic signs of EP, while the mean levels of $\beta$-hCG and CPK were higher in these patients than patients with normal ultrasonography, but difference was not significant ($p=0.37$ and $p=0.24$, respectively) (Table 3). The mean of $\beta$-hCG level was significantly lower in group 1 than group 2 (1187.52±631.45 vs. 1663.87±1096.845; $p=0.01$). The mean of CPK level was higher in group 1 than group 2 (71.98±15.711 vs. 64.43±15.898), but the difference was not significant ($p=0.06$) (Table 4).

### Table 1: Demographic characteristics of patients

| Marker            | Mean± SD   | P     |
|-------------------|------------|-------|
| Age (mean± SD)    | 28.7± 4.31 |       |
| Gestational age (mean± SD) | 45.67± 7.31 |       |
| Follow up (Week) (mean± SD) | 2.43± 0.77 |       |
| Gravid1           | 36 (45.6%) |       |
| Gravid 2 or more  | 43 (54.4%) |       |
| abortion          | 15 (19%)   |       |
| infertility       | 15 (19%)   |       |
| EP history        | 3 (3.8%)   |       |
| Pregnancy         | 67 (84.4%) |       |
| IVF               | 5 (6.3%)   |       |
| IUI               | 1 (1.3%)   |       |
| Clomiphene ,HMG   | 6 (7.6%)   |       |
| spotting          | 38 (48.1%) |       |
| Abdominal pain    | 31 (39.2%) |       |
| Group 1 (single dose MTX) | 58 (73.4%) |       |
| Group 2 (repeated dose or surgery) | 21 (26.6%) |       |
| Laparoscopy       | 9 (11.4%)  |       |
| Laparotomy        | 7 (8.9%)   |       |
| Second MTX dose   | 5 (6.4%)   |       |
| EP diagnosed in ultrasonography | 63 (79.7%) |       |

### Table 2: Correlation between $\beta$-hCG and CPK levels between normal and infertile patients

| Marker | History of infertility | n  | Mean± SD | P     |
|--------|------------------------|----|----------|-------|
| $\beta$-hCG | no | 64 | 1306.66± 841.074 | 0.86 |
|          | yes | 15 | 1346.07± 638.221 |       |
| CPK    | no | 64 | 70.58± 16.841 | 0.49 |
|        | yes | 15 | 67.40± 11.993 |       |

### Table 3: The mean ± SD of $\beta$-hCG and CPK levels in normal and EP patients

| Marker | Ultrasoundography | n  | Mean± SD | P     |
|--------|------------------|----|----------|-------|
| $\beta$-hCG | Normal | 16 | 1153.13± 589.746 | 0.37 |
|          | EP               | 63 | 1355.04± 847.680 |       |
| CPK    | Normal           | 16 | 65.75± 13.334 | 0.24 |
|        | EP               | 63 | 71.05± 16.548 |       |

### Table 4: The means of $\beta$-hCG and CPK levels in two groups

| Marker | Group | n  | Mean± SD | P     |
|--------|-------|----|----------|-------|
| $\beta$-hCG | success | 58 | 1187.52± 631.458 | 0.01 |
|          | failure | 21 | 1663.87± 1096.845 |       |
| CPK    | success | 58 | 71.98± 15.711 | 0.06 |
|        | failure | 21 | 64.43± 15.898 |       |
Discussion

In our experience, the success rate of MTX treatment was 58 (73.3%), which is lower than recent studies reporting success rates of 88 to 91 % (3,5,19). An explanation for such discrepancy between our experience and previous reports may due to different criteria in selection of patients, study design, and different definition of success. In current study, only patients responding to a single MTX injection were considered as treatment success group (group 1), but some studies considered patients with two or more injections as treatment success group (3,5). In current experience, when the CPK level on first day exceeded109 IU/L, the sensitivity and specificity of group 1 were about 35.3% and 100%, respectively. It explains that the positive predictive rate was 100%, which means that 100% of patients required surgical treatment or several MTX injections had a CPK level on first day <109 IU/L, while 100% of those with a CPK level>109 IU/L were successfully treated with a single MTX injection (19).

In line with this hypothesis, the mean of CPK was higher in group 1 than group 2 (71.98 ± 15.711 vs. 64.43 ± 15.898), but the difference was not significant (p=0.06). However, Gnisci et al. (2011) reported significant higher CPK plasma level in EP patients treated successfully compared to the control group (98±44 vs.69±18; p=0.004).They concluded that creatine phosphokinase level predicts outcome of women who were successfully treated for ectopic pregnancy with only a single injection of methotrexate(19).

Several studies indicated significant higher level of CPK in ectopic pregnancy (20-22). In a comparative study, Asgharnia et al. (2012) evaluated the role of serum creatine phosphokinase in diagnosis of tubal ectopic pregnancy. They enrolled 111 patients into three groups, and indicated that the mean CPK in group 1(EP) was significantly more than group 2(threatened abortion) and group 3(normal pregnancy) [ 96.27±63.9 u/lit (group 1) vs. 55.37±14.1 u/lit (group 2) and 48.94±19.2 u/lit (group 3); p=0.001].They deduced that determination of total CPK can enhance the diagnostic value of tubal pregnancy with only a single injection of methotrexate(19).

Relatively small sample size and absence of control group was two limitations of our experience. When the sample was not large enough, the obtained result could not indicate a significant difference in the CPK level, which seems to be the best indicator differentiating between the successful and unsuccessful treatment groups. Moreover, the present practice did not show any relation between initial hCG and CPK serum levels,(a finding indicating that they seem to be two independent biomarkers)We recommend more controlled studies with larger series in order to validate results reported here.

Acknowledgment

The authors would like to thank the nursing, administrative and secretarial staff of Department of Obstetrics and Gynecology at Shariati Hospital for their contribution to the maintenance of our patient record without which this project would have been impossible.
References

1. Kriebs JM, Fahey JO. Ectopic pregnancy. J Midwifery Womens Health 2006;51:431–9.
2. Condous G. Ectopic pregnancy—risk factors and diagnosis. Aust Fam Physician 2006;35:854–7.
3. Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med 2009;361:379–87.
4. Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gynecol 2010;115:495–502.
5. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol 2003;101:778–84.
6. Lipscomb GH, Givens VA, Meyer NL, Bran D. Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy. Fertil Steril 2004;81:1221-4.
7. Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005;192:1844–8.
8. Corsan GH, Karacan M, Qasim S, Bohrer MK, Ransom MX, Kemmann E. Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Hum Reprod 1995;10:2719-22.
9. Tanaka T, Hayashi H, Kutsuzawa T, Fujimoto S, Ichinoe K. Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case. Fertil Steril 1982;37:851–2.
10. Ory SI, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. Am J Obstet Gynecol 1986;154:1299–306.
11. Stovall TG, Ling FW, Gray LA, Carson SA, Buster JE. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstet Gynecol 1991;77:749–53.
12. Stovall TG, Ling FW. Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol 1993;168:1759–62.
13. Shalev E, Peleg D, Bustan M, Romano S, Tsbari A. Limited role for intratubal methotrexate treatment of ectopic pregnancy. Fertil Steril 1995;63:20-4.
14. Stiika CS, Anderson L, Frederiksen MC. Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience. Am J Obstet Gynecol 1996;174:1840-6.
15. Lipscomb GH, McCord ML, Stovall TG, Huff G, PorterasG, LingFW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999;341:1974-8.
16. DeveliogluOH, Askalli C, Uncu G, SamiliB, Daragenli O. Evaluation of serum creatine kinase in ectopic pregnancy with reference to tubal status and histopathology. BJOG 2002;109:121–8.
17. Birkhahn RH, Gaeta TJ, Leo PJ, Bove JJ. The utility of maternal creatine kinase in the evaluation of ectopic pregnancy. Am J Emerg Med 2000;18:695–7.
18. Katsikis I, Rouso D, Farmakiotis D, Kourtis A, Diamanti- Kandarakis E, Zournatz-Koivou V, et al. Creatine phosphokinase in ectopic pregnancy revisited: significant diagnostic value of its MB and MM isoenzyme fractions. Am J ObstetGynecol 2006;194:86–91.
19. Gnisci A, Rua S, Courbiere B, Cravello L, Gamerre M, Agostini A Plasma creatine phosphokinase level may predict successful treatment after a single injection of methotrexate for ectopic pregnancy. Fertil Steril 2011;95:2131–3.
20. Asgharnia M, Faraji R, Mirblouk F, Atrkar Roshan Z, Parvizi A. Evaluation of serum creatine phosphokinase in diagnosis of tubal ectopic pregnancy compared with intrauterine pregnancy and threatened abortion. Iranian Journal of Reproductive Medicine 2012; 10: 303-6.
21. Saha PK, Gupta I, Ganguly NK. Evaluation of serum creatine kinase as a diagnostic marker for tubal pregnancy.Aust N Z J ObstetGynaecol 1999; 39: 366-7.
22. Lavie O, Beller U, Neuman M, Ben-Chetrit A, Gottchshalk-Sabag S, Diamant YZ. Maternal serum creatine kinase: a possible predictor of tubal pregnancy. Am J Obstet Gynecol 1993; 169: 1149-50.
23. Birkhahn RH, Gaeta TJ, Paraschiv D, Bove JJ, Suzuki T, Kato H, et al. Serum levels of myoglobin, creatine phosphokinase, and smooth muscle heavy-chain myosin in patients with ectopic pregnancy. Ann Emerg Med 2001; 38: 628-32.
24. Cartwright J, Duncan WC, Critchley HO, Horne AW. Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities. Reproduction 2009; 138: 9-22.
25. Nowak-Markwitz E, Michalak M, Olejnik M, Spaczyński M. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril 2009;92:1203–7.
26. Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87:481–4.